Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) is a phase 3 interventional study registered as NCT04624204 by Merck Sharp & Dohme LLC, with 672 participants planned, started 2020-12-08 and due to reach its primary completion in 2027-10-28. Interventions recorded: Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Pembrolizumab placebo (saline), Olaparib 300 mg BID. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.